{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:38:08Z","timestamp":1789562288837,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40264-024-01436-2","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T12:01:28Z","timestamp":1717243288000},"page":"869-881","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5200-1638","authenticated-orcid":false,"given":"Adi","family":"Mor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Hashmueli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amnon","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Pinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifaat","family":"Safadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,1]]},"reference":[{"key":"1436_CR1","doi-asserted-by":"crossref","unstructured":"Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018;285:2944-71. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29637711","DOI":"10.1111\/febs.14466"},{"key":"1436_CR2","doi-asserted-by":"crossref","unstructured":"Mor A, Segal Salto M, Katav A, Barashi N, Edelshtein V, Manetti M, et al. Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis. Ann Rheum Dis. 2019;78:1260-8. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31129606","DOI":"10.1136\/annrheumdis-2019-215119"},{"key":"1436_CR3","doi-asserted-by":"crossref","unstructured":"Segal-Salto M, Barashi N, Katav A, Edelshtein V, Aharon A, Hashmueli S, et al. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. JHEP Rep. 2020;2:100064. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32039405","DOI":"10.1016\/j.jhepr.2019.100064"},{"key":"1436_CR4","doi-asserted-by":"crossref","unstructured":"Greenman R, Snir T, Levi O, Katav A, Lawler J, Thorburn D, et al. The role of CCL24 in primary sclerosing cholangitis: bridging patient serum proteomics to preclinical data. Cells. 2024;13(3):209. https:\/\/pubmed.ncbi.nlm.nih.gov\/38334601\/","DOI":"10.3390\/cells13030209"},{"key":"1436_CR5","unstructured":"Tabibian JH, Ali AH, Lindor KD. Primary sclerosing cholangitis, part 1: epidemiology, etiopathogenesis, clinical features, and treatment. Gastroenterol Hepatol (N Y). 2018;14:293-304. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29991937"},{"key":"1436_CR6","doi-asserted-by":"crossref","unstructured":"Nassir F. MASLD: mechanisms, treatments, and biomarkers. Biomolecules. 2022;12:824. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35740949","DOI":"10.3390\/biom12060824"},{"key":"1436_CR7","doi-asserted-by":"crossref","unstructured":"Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99:306-14. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20176408","DOI":"10.1016\/j.cmpb.2010.01.007"},{"key":"1436_CR8","doi-asserted-by":"crossref","unstructured":"Zheng C, Toth J, Bigwarfe T, MacDougall M, Jerath K, Bovat K, et al. Non-neutralizing antibodies increase endogenous circulating Ang1 levels. MAbs. 2018;10:1260-8. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30199300","DOI":"10.1080\/19420862.2018.1521130"},{"key":"1436_CR9","doi-asserted-by":"crossref","unstructured":"Kamath AV. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discov Today Technol. 2016;21-22:75-83. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27978991","DOI":"10.1016\/j.ddtec.2016.09.004"},{"key":"1436_CR10","doi-asserted-by":"crossref","unstructured":"Haraya K, Tachibana T, Nezu J. Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human. Drug Metab Pharmacokinet. 2017;32:208-17. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28734646","DOI":"10.1016\/j.dmpk.2017.05.002"},{"key":"1436_CR11","doi-asserted-by":"crossref","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6:576-88. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28653357","DOI":"10.1002\/psp4.12224"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01436-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01436-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01436-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T14:24:03Z","timestamp":1723645443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01436-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1436"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01436-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]},"assertion":[{"value":"17 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Chemomab Therapeutics Ltd. Chemomab had the opportunity to review the manuscript for factual accuracy; the authors maintained full control of the manuscript and determined the final content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SF served as a consultant for 89 Bio, Amgen, Axcella Health, Blade Therapeutics, Bristol Myers Squibb, Can-Fite Biopharma, Casma Therapeutics, Chemomab, Escient Pharmaceuticals, Forbion, Galmed, Gordian Biotechnology, Glycotest, Glympse Bio, In sitro, Morphic Therapeutics, North Sea Therapeutics, Novartis, Ono Pharmaceuticals, Pfizer Pharmaceuticals, Scholar Rock, and Surrozen. He holds stock in Blade Therapeutics, Escient, Galectin, Galmed, Genfit, Glympse, Hepgene, Lifemax, Metacrine, Morphic Therapeutics, Nimbus, North Sea Therapeutics, Scholar Rock, and Surrozen. AP has served as a consultant for Chemomab Therapeutics Ltd. MP has served as a consultant for Astra Zeneca, Boehringer Ingelheim, Chemomab, Dicerna, Galecto, LimmaTech Biologics, Promethera, Resolution Therapeutics, and Takeda. He is a cofounder, consultant, and shareholder of Engitix Therapeutics Ltd and 3P-Sense Ltd. He is a chief medical advisor of Hepatotargets BitBio Ltd. RS has received grant\/research financial support, served as a consultant, and participated in speakers\u2019 bureaus for Chemomab Therapeutics Ltd. AM, SH, and MF are full-time employees of Chemomab Therapeutics Ltd and may hold Chemomab stock and\/or options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All studies were conducted in accordance with the Good Clinical Practice Guideline as defined by the International Conference on Harmonization and the Declaration of Helsinki. All study participants provided written informed consent prior to any study activity. The protocol, amendments, and informed consent forms for the Phase 1a studies were approved by the Tel Aviv Souraski Medical Center ethics committee; for the Phase 1b MASLD study, informed consent forms, protocol and amendments were approved by the Hadassah Medical Center institutional review board. Ethics committee approval numbers: TLV-0251-17, 0824-18-TLV , 0117-18-HMO,","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All subjects signed informed consent to participate in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Chemomab Therapeutics, Ltd is committed to responsible sharing of data from clinical trials sponsored by Chemomab. This includes summary and anonymized individual patient data, as well as other information (e.g., protocols). Requests for data from any qualified researchers who engage in rigorous, independent scientific research will be considered as long as the clinical trial data are not part of an ongoing or planned regulatory submission. Original data will be available for 5 years, beginning 3 months after approval of the study drug for use in patients. Send data access proposals to Medinfo@chemomab.com.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"AM, SF, SH, AP, MP, and RS participated in the study concept and design. AM and RS were involved in the data acquisition. AM and SH conducted the statistical analysis. AM, SF, SH, MP, MF and RS interpreted the data. All authors critically reviewed and edited the manuscript and provided final approval.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}